United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - rifapentine (unii: xjm390a33u) (rifapentine - unii:xjm390a33u) - rifapentine 150 mg - priftin® (rifapentine) is indicated in adults and children 12 years and older for the treatment of active pulmonary tuberculosis (tb) caused by mycobacterium tuberculosis . priftin must always be used in combination with one or more antituberculosis (anti-tb) drugs to which the isolate is susceptible [see dosage and administration (2.1) and clinical studies (14.1)]. limitations of use do not use priftin monotherapy in either the initial or the continuation phases of active antituberculous treatment. priftin should not be used once weekly in the continuation phase regimen in combination with isoniazid (inh) in hiv-infected patients with active pulmonary tuberculosis because of a higher rate of failure and/or relapse with rifampin (rif)-resistant organisms [see warnings and precautions (5.4) and clinical studies (14.1)]. priftin has not been studied as part of the initial phase treatment regimen in hiv-infected patients with active pulmonary tuberculosis. priftin is indicated in adults and children 2 years an

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

sanofi-aventis (malaysia) sdn. bhd. - docetaxel trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - hydrochlorothiazide; irbesartan -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rasburicase -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan; hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - irbesartan; hydrochlorothiazide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - diltiazem hydrochloride -

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - diltiazem hydrochloride 60mg - film coated tablet - 60 mg - active: diltiazem hydrochloride 60mg excipient: colloidal silicon dioxide hypromellose lactose monohydrate magnesium stearate methyl hydroxybenzoate microcrystalline cellulose opadry quinoline yellow sunset yellow fcf - patients with moderate to severe angina pectoris due to atherosclerotic coronary artery disease or coronary artery spasm (vasospastic angina).

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - powder for injection - 10,000ku - active: asparaginase 10000 [iu] (derived from cultures of e.coli hap ex japan, expressed as 10,000ku) - treatment of acute lymphoblastic leukaemia

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - ramipril hydrochlorothiazide - tablets - 2.5/12.5 milligram